Publications

Radionuclide calibrator responses for 224Ra in solution and adsorbed on calcium carbonate microparticles. By Elisa Napoli, Jeffrey T.Cessna, Leticia Pibida, Ryan Fitzgerald, Gro E.Hjellum, Denis E. Bergeron
Primary standardization of 224RA activity by liquid scintillation counting. Elisa Napoli, Jeffrey T. Cessna, Ryan Fitzgerald, Leticia Pibida, Ronald Collé, Lizbeth Laureano-Pérez, Brian E. Zimmerman, Denis E.Bergeron; Applied Radiation and Isotopes Volume 155, January 2020, 108933 (external link)
Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice. Westrøm S, Malenge M, Jorstad IS, Napoli E, Bruland Ø, Bønsdorff TB, Larsen R; J Labelled Comp Radiopharm. 2018 May 30;61(6):472-486.
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma. Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH. PLoS One. 2016 Oct 24;11(10)
Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer. Westrøm S, Bønsdorff TB, Bruland ØS, Larsen RH. Translational Oncology. 2018 Jan 27;11:259-267
Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution. Westrøm S, Generalov R, Bønsdorff TB, Larsen RH. Nuclear Medicine and Biology. 2017 Apr 26;51:1-9
Release and retention of 212Pb from 224Ra-labeled microparticles. Napoli E, Westrøm S, Bønsdorff TB, Bruland Ø, Larsen R.; The Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2018 Annual Meeting in Philadelphia, USA

Posters

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

Largest shareholders

IR Contact

+47 22 18 33 05

Oncoinvent AS Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.

close